Cargando…

Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease

Background: Interstitial lung disease (ILD) is one of the leading causes of mortality in patients with systemic sclerosis (SSc). To further understand this patient population, we present the first systematic review on the epidemiology of SSc and SSc-associated ILD (SSc-ILD). Methods: Bibliographic d...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergamasco, Aurore, Hartmann, Nadine, Wallace, Laura, Verpillat, Patrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497473/
https://www.ncbi.nlm.nih.gov/pubmed/31114386
http://dx.doi.org/10.2147/CLEP.S191418
_version_ 1783415476147191808
author Bergamasco, Aurore
Hartmann, Nadine
Wallace, Laura
Verpillat, Patrice
author_facet Bergamasco, Aurore
Hartmann, Nadine
Wallace, Laura
Verpillat, Patrice
author_sort Bergamasco, Aurore
collection PubMed
description Background: Interstitial lung disease (ILD) is one of the leading causes of mortality in patients with systemic sclerosis (SSc). To further understand this patient population, we present the first systematic review on the epidemiology of SSc and SSc-associated ILD (SSc-ILD). Methods: Bibliographic databases and web sources were searched for studies including patients with SSc and SSc-ILD in Europe and North America (United States and Canada). The systematic review was limited to publications in English, German, French, Spanish, Italian, and Portuguese, published between January 1, 2000 and February 29, 2016. For all publications included in the review, the methodologic quality was assessed. For each dimension and region, data availability in terms of quantity and consistency of reported findings was evaluated. Results: Fifty publications reporting epidemiologic data (prevalence, incidence, demographic profile, and survival and mortality) were included; 39 included patients with SSc and 16 included patients with SSc-ILD. The reported prevalence of SSc was 7.2–33.9 and 13.5–44.3 per 100,000 individuals in Europe and North America, respectively. Annual incidence estimates were 0.6–2.3 and 1.4–5.6 per 100,000 individuals in Europe and North America, respectively. Associated ILD was present in ~35% of the patients in Europe and ~52% of the patients in North America. In Europe, a study estimated the prevalence and annual incidence of SSc-ILD at 1.7–4.2 and 0.1–0.4 per 100,000 individuals, respectively. In both Europe and North America, SSc-ILD was diagnosed at a slightly older age than SSc, with both presentations of the disease affecting 2–3 times more women than men. Ten-year survival in patients with SSc was reported at 65–73% in Europe and 54–82% in North America, with cardiorespiratory manifestations (including ILD) associated with poor prognosis. Conclusion: This systematic review confirms that SSc and SSc-ILD are rare, with geographic variation in prevalence and incidence.
format Online
Article
Text
id pubmed-6497473
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-64974732019-05-21 Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease Bergamasco, Aurore Hartmann, Nadine Wallace, Laura Verpillat, Patrice Clin Epidemiol Original Research Background: Interstitial lung disease (ILD) is one of the leading causes of mortality in patients with systemic sclerosis (SSc). To further understand this patient population, we present the first systematic review on the epidemiology of SSc and SSc-associated ILD (SSc-ILD). Methods: Bibliographic databases and web sources were searched for studies including patients with SSc and SSc-ILD in Europe and North America (United States and Canada). The systematic review was limited to publications in English, German, French, Spanish, Italian, and Portuguese, published between January 1, 2000 and February 29, 2016. For all publications included in the review, the methodologic quality was assessed. For each dimension and region, data availability in terms of quantity and consistency of reported findings was evaluated. Results: Fifty publications reporting epidemiologic data (prevalence, incidence, demographic profile, and survival and mortality) were included; 39 included patients with SSc and 16 included patients with SSc-ILD. The reported prevalence of SSc was 7.2–33.9 and 13.5–44.3 per 100,000 individuals in Europe and North America, respectively. Annual incidence estimates were 0.6–2.3 and 1.4–5.6 per 100,000 individuals in Europe and North America, respectively. Associated ILD was present in ~35% of the patients in Europe and ~52% of the patients in North America. In Europe, a study estimated the prevalence and annual incidence of SSc-ILD at 1.7–4.2 and 0.1–0.4 per 100,000 individuals, respectively. In both Europe and North America, SSc-ILD was diagnosed at a slightly older age than SSc, with both presentations of the disease affecting 2–3 times more women than men. Ten-year survival in patients with SSc was reported at 65–73% in Europe and 54–82% in North America, with cardiorespiratory manifestations (including ILD) associated with poor prognosis. Conclusion: This systematic review confirms that SSc and SSc-ILD are rare, with geographic variation in prevalence and incidence. Dove 2019-04-18 /pmc/articles/PMC6497473/ /pubmed/31114386 http://dx.doi.org/10.2147/CLEP.S191418 Text en © 2019 Bergamasco et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Bergamasco, Aurore
Hartmann, Nadine
Wallace, Laura
Verpillat, Patrice
Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease
title Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease
title_full Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease
title_fullStr Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease
title_full_unstemmed Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease
title_short Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease
title_sort epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497473/
https://www.ncbi.nlm.nih.gov/pubmed/31114386
http://dx.doi.org/10.2147/CLEP.S191418
work_keys_str_mv AT bergamascoaurore epidemiologyofsystemicsclerosisandsystemicsclerosisassociatedinterstitiallungdisease
AT hartmannnadine epidemiologyofsystemicsclerosisandsystemicsclerosisassociatedinterstitiallungdisease
AT wallacelaura epidemiologyofsystemicsclerosisandsystemicsclerosisassociatedinterstitiallungdisease
AT verpillatpatrice epidemiologyofsystemicsclerosisandsystemicsclerosisassociatedinterstitiallungdisease